Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C

Journal of Clinical Gastroenterology

Volumn 41, Issue 6, 2007, Pages 616-623

  Watanabe, Naoko ^a   Ikeda, Hitoshi ^a,b   Nakamura, Kazuhiro ^a   Ohkawa, Ryunosuke ^a   Kume, Yukio ^a   Aoki, Junken ^b   Hama, Kotaro ^b   Okudaira, Shinichi ^b   Tanaka, Masayuki ^b   Tomiya, Tomoaki ^a   Yanase, Mikio ^a   Tejima, Kazuaki ^a   Nishikawa, Takako ^a   Arai, Masahiro ^c   Arai, Hiroyuki ^b   Omata, Masao ^a   Fujiwara, Kenji ^d   Yatomi, Yutaka ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOSHIBA GENERAL HOSPITAL   (Japan)

^d YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Lysophosphatidylcholine; Lysophospholipase D; Lysophospholipid

Indexed keywords

ALBUMIN; AUTOTAXIN; CHOLINE; HYALURONIC ACID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOCYTE COUNT;

AGED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PLATELET COUNT; PYROPHOSPHATASES; SUBSTRATE CYCLING;

EID: 34250770503     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225642.90898.0e     Document Type: Article

References (47)

1. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004;26:870-881.
2. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res. 1999;253:230-238.
3. van Corven EJ, Groenink A, Jalink K, et al. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell. 1989;59:45-54.
4. Tokumura A, Iimori M, Nishioka Y, et al. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol. 1994;267:C204-C210.
5. Piazza GA, Ritter JL, Baracka CA. Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp Cell Res. 1995;216:51-64.
6. Schumacher KA, Classen HG, Spath M. Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb Haemost. 1979;42:631-640.
7. Tokumura A, Fukuzawa K, Yamada S, et al. Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregnant rats. Arch Int Pharmacodyn Ther. 1980;245:74-83.
8. Imamura F, Shinkai K, Mukai M, et al. rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Int J Cancer. 1996;65:627-632.
9. Levine JS, Koh JS, Triaca V, et al. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol. 1997;273:F575-F585.
10. Ikeda H, Yatomi Y, Yanase M, et al. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun. 1998;248:436-440.
11. Yanase M, Ikeda H, Matsui A, et al. Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem Biophys Res Commun. 2000;277: 72-78.
12. Yanase M, Ikeda H, Ogata I, et al. Functional diversity between Rho-kinase- and MLCK-mediated cytoskeltal actions in a myofibroblast-like hepatic stellate cell line. Biochem Biophys Res Commun. 2003;305:223-228.
13. Ikeda H, Nagashima K, Yanase M, et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2003;285:G880-G886.
14. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158:227-233.
15. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277:39436-39442.
16. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267:2524-2529.
17. Stracke ML, Clair T, Liotta LA. Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv Enzyme Regul. 1997;37: 135-144.
18. Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737-48744.
19. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719-723.
20. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998;9:437-442.
21. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001;290:302-313.
22. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223-1232.
23. Baker DL, Morrison P, Miller B, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 2002;287:3081-3082.
24. Macey M, Azam U, McCarthy D, et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem. 2002;48:891-899.
25. Kishimoto T, Matsuoka T, Imamura S, et al. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta. 2003;333:59-67.
26. Tanaka M, Kishi Y, Takanezawa Y, et al. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett. 2004;571:197-204.
27. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19: 1513-1520.
28. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-1381.
29. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-1713.
30. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935-942.
31. Guechot J, Poupon RE, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol. 1994;20:388-393.
32. Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc. 1980;55:360-364.
33. van der Bend RL, de Widt J, van Corven EJ, et al. Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts. Biochim Biophys Acta. 1992;1125:110-112.
34. Brindley DN, Waggoner DW. Mammalian lipid phosphate phosphohydrolases. J Biol Chem. 1998;273:24281-24284.
35. Sciorra VA, Morris AJ. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta. 2002;1582: 45-51.
36. Yue J, Yokoyama K, Balazs L, et al. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal. 2004;16:385-399.
37. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993;328:1828-1835.
38. Minato Y, Hasumura Y, Takeuchi J. The role of fat-storing cells in Disse space fibrogenesis in alcoholic liver disease. Hepatology. 1983;3:559-366.
39. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102:538-549.
40. Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001;48:548-557.
41. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology. 2001;121:685-698.
42. Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 1992;90:642-646.
43. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001;21:337-349.
44. Chijiiwa K, Nakano K, Kameoka N, et al. Proliferating cell nuclear antigen, plasma fibronectin, and liver regeneration rate after seventy percent hepatectomy in normal and cirrhotic rats. Surgery. 1994;116:544-549.
45. Hashimoto M, Watanabe G. Functional capacity of the cirrhotic liver after partial hepatectomy in the rat. Surgery. 1999;126:541-547.
46. Andiran F, Ayhan A, Tanyel FC, et al. Regenerative capacities of normal and cirrhotic livers following 70% hepatectomy in rats and the effect of alpha-tocopherol on cirrhotic regeneration. J Surg Res. 2000;89:184-188.
47. Masson S, Scotte M, Francois A, et al. Changes in growth factor and cytokine mRNA levels after hepatectomy in rat with CCl(4)-induced cirrhosis. Am J Physiol. 1999;277:G838-G846.